{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T17:37:41Z","timestamp":1789580261480,"version":"build-2803163510"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T00:00:00Z","timestamp":1689120000000},"content-version":"am","delay-in-days":345,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000071","name":"National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["Medicines360"],"award-info":[{"award-number":["Medicines360"]}],"id":[{"id":"10.13039\/100000071","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010174","name":"University of Colorado","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010174","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000801","name":"Bayer HealthCare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000801","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006668","name":"Oregon Health and Science University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006668","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","contraceptionjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contraception"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.contraception.2022.04.002","type":"journal-article","created":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T19:19:57Z","timestamp":1649963997000},"page":"54-60","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Evaluation of ovulation and safety outcomes in a multi-center randomized trial of three 84 day ulipristal acetate regimens"],"prefix":"10.1016","volume":"112","author":[{"given":"Carolyn L","family":"Westhoff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David F.","family":"Archer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"Barnhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Darney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Gilliam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Teal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana L","family":"Blithe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.contraception.2022.04.002_bib0001","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S0039-128X(03)00118-1","article-title":"Development of the selective progesterone receptor modulator CDB-2914 for clinical indications","volume":"68","author":"Blithe","year":"2003","journal-title":"Steroids"},{"issue":"1","key":"10.1016\/j.contraception.2022.04.002_bib0002","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1210\/jcem.87.1.8140","article-title":"Daily low-dose mifepristone has contraceptive potential by suppressing ovulation and menstruation: A double-blind randomized control trial of 2 and 5 mg per day for 120 days","volume":"87","author":"Brown","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.contraception.2022.04.002_bib0003","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1093\/humrep\/dem177","article-title":"A novel estrogen-free oral contraceptive pill for women: multicenter double-blind, randomized controlled trial of mifepristone and progestogen-only pill (levonorgestrel)","volume":"22","author":"Lahka","year":"2007","journal-title":"Human Reproduction"},{"key":"10.1016\/j.contraception.2022.04.002_bib0004","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1210\/clinem\/dgz139","article-title":"The selective progesterone receptor modulator ulipristal acetate inhibits the activity of the glucocorticoid receptor","volume":"10593","author":"Small","year":"2020","journal-title":"J Clin Endocrin Metab"},{"issue":"5","key":"10.1016\/j.contraception.2022.04.002_bib0005","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1097\/01.AOG.0000239440.02284.45","article-title":"Progesterone receptor modulator for emergency contraception: A randomized controlled trial","volume":"108","author":"Creinin","year":"2006","journal-title":"Obstet Gynecol"},{"issue":"10","key":"10.1016\/j.contraception.2022.04.002_bib0006","first-page":"60101","article-title":"Ulipristal acetate versus levonorgestrel for emergency contraception: a randomized non-inferiority trial and meta-analysis","volume":"375","author":"Glasier","year":"2010","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.contraception.2022.04.002_bib0007","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.contraception.2011.02.009","article-title":"Can we identify women at risk of pregnancy despite using emergency contraception? Data from randomized trials of ulipristal acetate and levonorgestrel","volume":"84","author":"Glasier","year":"2011","journal-title":"Contraception"},{"issue":"9","key":"10.1016\/j.contraception.2022.04.002_bib0008","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1210\/jc.2006-2816","article-title":"Effects of the progesterone receptor modulator VA2914 in a continuous low dose on the hypothalamic-pituitary-ovarian axis and endometrium in normal women: a prospective, randomized, placebo-controlled trial","volume":"92","author":"Chabbert-Buffet","year":"2007","journal-title":"J Clin Endocrin Metab"},{"key":"10.1016\/j.contraception.2022.04.002_bib0009","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.contraception.2011.10.003","article-title":"Effects of a novel estrogen-free, progesterone receptor modulator contraceptive vaginal ring on inhibition of ovulation, bleeding patterns and endometrium in normal women","volume":"85","author":"Brache","year":"2012","journal-title":"Contraception"},{"issue":"6","key":"10.1016\/j.contraception.2022.04.002_bib0010","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.contraception.2014.08.006","article-title":"A randomized study on pharmacodynamic effects of vaginal rings delivering the progesterone receptor modulator ulipristal acetate: Research for a novel estrogen-free method of contraception","volume":"90","author":"Huang","year":"2014","journal-title":"Contraception"},{"issue":"5","key":"10.1016\/j.contraception.2022.04.002_bib0011","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1056\/NEJMoa1103182","article-title":"Ulipristal acetate versus placebo for fibroid treatment before surgery","volume":"366","author":"Donnez","year":"2012","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.contraception.2022.04.002_bib0012","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/j.fertnstert.2014.02.008","article-title":"Long-term treatment of uterine fibroids with ulipristal acetate","volume":"101","author":"Donnez","year":"2014","journal-title":"Fertil Steril"},{"issue":"RR04","key":"10.1016\/j.contraception.2022.04.002_bib0013","first-page":"1","article-title":"U.S. Medical Eligibility Criteria for Contraceptive Use, 2010","volume":"59","author":"Curtis","year":"2010","journal-title":"MMWR Recomm Rep 2010"},{"key":"10.1016\/j.contraception.2022.04.002_bib0014","doi-asserted-by":"crossref","unstructured":"Praditpan P, Hamouie A, Basaraba CN, Nandakumar R, Cremers S, Davis AR, et\u00a0al. Pharmacokinetics of levonorgestrel and ulipristal acetate emergency contraception in women with normal and obese body mass index. Contraception. 2017:464-9. doi: 10.1016\/j.contraception.2017.01.004","DOI":"10.1016\/j.contraception.2017.01.004"},{"key":"10.1016\/j.contraception.2022.04.002_bib0015","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/AOG.0b013e3181e79440","article-title":"Ovarian suppression in normal-weight and obese women during oral contraceptive use","volume":"117","author":"Westhoff","year":"2010","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2022.04.002_bib0016","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.contraception.2009.04.011","article-title":"Impact of obesity on oral contraceptive pharmacokinetics and hypothalamic-pituitary-ovarian activity","volume":"80","author":"Edelman","year":"2009","journal-title":"Contraception"},{"issue":"4","key":"10.1016\/j.contraception.2022.04.002_bib0017","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.fertnstert.2018.06.044","article-title":"Liver injury and ulipristal acetate: an overstated tragedy?","volume":"110","author":"Donnez","year":"2018","journal-title":"Fertil Steril"},{"key":"10.1016\/j.contraception.2022.04.002_bib0018","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.contraception.2015.01.008","article-title":"A review of the endometrial histologic effects of progestins and progesterone receptor modulators in reproductive age women","volume":"91","author":"Dinh","year":"2015","journal-title":"Contraception"}],"container-title":["Contraception"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001078242200107X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001078242200107X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T21:12:13Z","timestamp":1762117933000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001078242200107X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":18,"alternative-id":["S001078242200107X"],"URL":"https:\/\/doi.org\/10.1016\/j.contraception.2022.04.002","relation":{},"ISSN":["0010-7824"],"issn-type":[{"value":"0010-7824","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of ovulation and safety outcomes in a multi-center randomized trial of three 84 day ulipristal acetate regimens","name":"articletitle","label":"Article Title"},{"value":"Contraception","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.contraception.2022.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}